Antibody immunoglobulin G (IgG) against human prostatic specific antigen (PSA) as a carrier protein for chemotherapeutic drugs to human prostate tumors: Part 1. A double immunofluorescence analysis

Anatomical Record

Volumn 245, Issue 4, 1996, Pages 652-661

  Sinha, Akhouri A ^a,b   Sackrison, James L ^d   DeLeon, Onofrea F ^a   Wilson, Michael J ^a,c   Gleason, Donald F ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d Lakeland Biomedical   (United States)

Author keywords

5' fluorouracil; Carrier protein; Immunoconjugate prostate treatment; Prostatic epithelial cells; Prostatic tumor cells; PSA IgG; PSA IgG drug immunoconjugate

Indexed keywords

FLUOROURACIL DERIVATIVE; IMMUNOGLOBULIN G ANTIBODY; PROSTATE SPECIFIC ANTIGEN;

ANTIGEN BINDING; ARTICLE; CANCER IMMUNOTHERAPY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; TARGET CELL;

ANTIBODIES; ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; DRUG CARRIERS; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT ANTIBODY TECHNIQUE; FLUORESCENT DYES; HUMANS; IMMUNOGLOBULIN G; IMMUNOTOXINS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RHODAMINES; TISSUE DISTRIBUTION;

EID: 0029798121     PISSN: 0003276X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0185(199608)245:4<652::AID-AR5>3.0.CO;2-Q     Document Type: Article

References (50)

1. Akerblom, E., M. Dohlsten, C. Bryno, M. Mastej, I. Steringer, G. Hedlund, P. Lande, and T. Kalland 1993 Preparation and characterization of conjugates of monoclonal antibodies and staphylococcal enteroxtoxin A using a new hydrophilic gross-linker. Bioconjug. Chem., 4:455-466.
2. Albrecht, S., H. Brandl, M. Steinke, and T. Freidt 1994 Chemiluminescent enzyme immunoassay of prostatic specific antigen based on indoxyl phosphate substrate. Clin. Chem., 40:1970-1971.
3. Benchimol, S. and V. Ling 1994 P-glycoprotein and tumor progression. J. Natl. Cancer Inst., 86:814-816.
4. Blumenstein, B., D.E. Crawford, J.H. Saiers, R.L. Stephens, S.E. Rivkin, and C.A. Coltman, Jr. 1993 Doxorubicin, mitomycin and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: A southwest oncology group study. J. Urol., 150:411-413.
5. Brinkmann, U., M. Gallo, E. Brinkmann, S. Kumar, and I. Pastan 1993 A recombinant immunotoxin that is active on prostate cells and that is composed of the Fv region of monoclonal antibody PR1 and a truncated form of Pseudomonas exotoxin. Proc. Natl. Acad. Sci. USA, 90:547-551.
6. Choe, B.K. 1994 Conjugating antibodies to ligands, enzymes, and metallic particles. In: Antibody Techniques. V.S. Malik and E.P. Lillehoj, eds. Academic Press, New York, pp 221-225.
7. Cumber, A.J., J.A. Forrester, B.M.J. Foxwell, W.C.J. Ross, and P.E. Thorpe 1985 Preparation of antibody-toxin conjugates. Methods Enzymol., 112:207-225.
8. Dietrick, D.D., J.E. McNeal, and T.A. Stamey 1995 Core cancer length in ultrasound-guided systematic sextant biopsies: A preoperative evaluation of prostate cancer volume. Urology, 45:987-992.
9. Dillman, R.O. 1994 The clinical experience with interleukin-2 in cancer therapy. Cancer Biotherapy, 9:183-209.
10. Dzik, J.M., T. Kulikowski, Z. Zielinski, J. Ciesla, W. Rode, and D. Shugar 1987 Interaction of 5-fluoro-4-thio-2′-deoxyuridine 5′-phosphate with mammalian tumor thymidylate synthase: Role of the pyrimidine N(3)-H dissociation. Biochem. Biophys. Res. Comm., 149:1200-1207.
11. Ellis, J.W., and M.K. Brawer 1993 The role of tumor markers in the diagnosis and treatment of prostate cancer. In: Prostate Diseases. Chap. 22. H. Lepor and R.K. Lawson, eds. W.B. Saunders, Philadelphia, pp. 276-292.
12. Endicott, J.A., and V. Ling 1989 The biochemistry of P-glycoprotein-mediated multidrug resistance. Ann. Rev. Biochem., 58:137-171.
13. Epstein, J.I., G. Pizov, and P.C. Walsh 1993 Correlation of pathologic findings with progression after radical retropubic prostatectomy Cancer, 71:3582-3593.
14. FitzGerald, D., and I. Pastan 1989 Targeted toxin therapy for the treatment of cancer. J. Natl. Cancer Inst., 81:1455-1463.
15. Fotsis, T., Y. Zhang, M.S. Pepper, A. Herman, R. Montesano, P.P. Nawroth, and L Schweigerer 1994 The endogenous oestrogen metabolite 2-methoxyoestradial inhibits angiogenesis and suppresses tumor growth. Nature, 368:237-239.
16. Garnick, M.B. 1993 Prostate cancer: Screening, diagnosis, and management. Ann Inter. Med., 118:804-818.
17. Gleason, D.F. 1992 Histologic grading of prostate cancer. Hum. Pathol., 23:273-279.
18. Goerlach, A., K.G. Krauer, I.F.C. McKenzie, and G.A. Pietersz 1991 In vitro antitumor activity of 2′-deoxy-5-fluorouridine-monoclonal antibody conjugates. Bioconjugate Chem., 2:96-101.
19. Griffiths, K., C.L. Eaton, M.E. Harper, A. Turkes, and W.B. Peeling 1994 Hormonal treatment of advanced disease: Some newer aspects. Surg. Oncol., 21:672-687.
20. Johnston, P.G., J.H. Lenz, C.G. Leichman, K.D. Danenberg, C.J. Allegra, P.V. Danenberg, and L. Leichman 1995 Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res., 55:1407-1412.
21. Johnston, P.G., C.M. Liang, S. Henry, B.A. Chabner, and C.J. Allegra 1991 Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue. Cancer Res., 51:6668-6676.
22. Krauer, K.G., I.F.C. McKenzie, and G.A. Pietersz 1992 Antitumor effect of 2′-deoxy-5-fluorouridine conjugates against a murine thymoma and colon carcinoma xenografts. Cancer Res., 32:132-137.
23. Kuzel, T.M., M.S. Tallman, D. Shevrin, E. Braud, L. Kilton, P. Johnson, J. Kozlowski, N.J. Vogelzang, R. Blough, and A.B. Benson, in 1993 A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. Cancer, 72:1965-1968.
24. Liu, L., and D.V. Santi 1994 5-fluoro-2′-deoxycytidine5′-monophosphate is a mechanism-based inhibitor of thymidylate synthase. Biochim. Biophys. Acta, 1209:89-94.
25. Melpas, J.S. 1991 Chemotherapy. In: Introduction to the Cellular and Molecular Biology of Cancer. L.M. Franks and N.M. Teich, eds. Oxford University Press, Oxford, pp. 451-467.
26. Monne, M., C.M. Croce, H. Yu, and E.P. Diamandis 1994 Molecular characterization of prostatic specific antigen messenger RNA expressed in breast tumors. Cancer Res., 54:6344-6347.
27. Mostofi, F.K., C.J. Davis, Jr., and I.A. Sesterhenn 1993 Histopathology of prostate cancer. In: Prostate Diseases. Chap. 19. H. Lepor and R.K. Lawson, eds. W.B. Saunders, Philadelphia, pp. 229-256.
28. Myers, D., F. Uckun, S. Swaim, and D. Vallera 1989 The effects of aromatic and aliphatic malemide crosslinkers on anti-CD5 ricin immunotoxins. J. Immuno. Meth., 121:129-142.
29. O'Reilly, M.S., L. Holmgren, Y. Shing, C. Chen, R.A. Rosenthal, M. Moses, W.S. Lane, Y. Cao, E.H. Sage, and J. Folkman 1994 Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79:315-328.
30. Pietersz, G.A., and K. Krauer 1994 Antibody-targeted drugs for the therapy of cancer. J. Drug Targeting, 2:183-215.
31. Pietersz, G.A., A. Rowland, M.J. Smyth, and I.F.C. Mckenzie 1994 Chemoimmunoconjugates for the treatment of cancer. Adv. Immunol., 56:301-387.
32. Pietersz, G.A. 1990 The linkage of cytotoxic drugs to monoclonal antibodies for the treatment of cancer. Bioconjug. Chem., 1:89-95.
33. Rosen, M.A. 1995 Impact of proetatic-specific antigen screening on the natural history of prostate cancer. Urology, 46:757-768.
34. Ruckle, H.C., G.G. Klee, and J.E. Oesterling 1994 Prostatic specific antigen: critical issues for the practicing physician. Mayo Clin. Proc., 69:59-79.
35. Sakai, H., Y. Yogi, Y. Minami, Y. Yushita, H. Kanetake, and Y. Saito 1993 Prostatic specific antigen and prostatic acid phosphatase immunoreactivity as prognostic indicators of advanced prostatic carcinoma. J. Urol., 149:1020-1023.
36. Sinha, A.A., M.J. Wilson, D.F. Gleason, P.K. Reddy, M. Sameni, and B.F. Sloane 1995 Immunohistochemical localization of cathepsin B in neoplastic human prostate. Prostate, 26:171-178.
37. Sinha, A.A., D.F. Gleason, M.J. Wilson, M.R. Wick, P.K. Reddy, and C.E. Blackard 1988 Relationship of prostatic acid phosphatase localization in human prostate by a monoclonal antibody with the Gleason grading system. Prostate, 13:1-15.
38. Sinha, A.A., M.J. Wilson, and D.F. Gleason 1987 Immunoelectron microscopic localization of prostatic specific antigen in human prostate by the protein A-gold complex. Cancer, 60:1288-1293.
39. Sinha, A.A., K.A. Hagen, R.K. Sibley, M.J. Wilson, C. Limas, P.K. Reddy, C.E. Blackard, and D.F. Gleason 1986 Analysis of fixation effects on immunohistochemical localization of prostatic specific antigen in human prostate. J. Urol., 136:722-727.
40. Sinha, A.A., C.E. Blackard, U.S. Seal 1977 A critical analysis of tumor morphology and hormone treatments in the untreated and estrogen-treated responsive and refractory human prostatic carcinoma. Cancer, 40:2836-2850.
41. Sloane B.F. and I.M. Berquin 1994 Proteases and cancer: an introduction. In: Proteolysis and Protein Turnover. J.S. Bond and A.J. Barrett, eds. Portland Press, London, pp. 225-231.
42. Steele, Jr. G.D., R.T. Osteen, D.P. Winchester, G.P. Murphy, and H.R. Menck 1994 Clinical highlights from the National Cancer Data Base. CA Cancer J. Clin., 44:71-80.
43. Takayama, T.K., R.L. Vessella, and P.H. Lange 1994 Newer applications of serum-prostatic-specific antigen in the management of prostate cancer. Sem. Oncol., 21:542-553.
44. Theyer, G., M. Schirmback, T. Thalhammer, E.R. Sherwood, G. Baumgartner, and G. Hamilton 1993 Role of the Mdr-1-encoded multiple drug resistance phenotype in prostate cancer cell lines. J. Urol., 150:1544-1547.
45. Tijssen, P. 1985 Practice and Theory of Enzyme Immunoassays. Elsevier, New York, pp. 237-239.
46. Tomita, T., D. Timothy, K. Simon, S. Lee, N. Mark, and C. Masahiro 1993 Profile of prostatic specific antigen in prostatic carcinomas. Mod. Pathol., 6:259-264.
47. Uchida, M., N. Brown, D.H.W. Ho 1990 Enzymatic conversion of 5-fluoro-2′-deoxyuridine to 5-fluorouracil or 5-fluoro-2′-deoxyuridine 5′-monophosphate in human tissues. Anticancer Res., 10: 779-784.
48. Webb, K.S., S.H.M. Poulton, S.N. Liberman, and P.J. Walther 1989 Rationale for immunotoxin therapy of metastatic prostate carcinoma formatted as a multi-stage delivery system. J. Urol., 142: 425-432.
49. Whiteley, J., I. Jerkunica, and T. Deits 1974 Thymidine synthetase from Amethopteri-Resistant Lactobacillis casei. Purification by affinity chromatography. Biochem., 13:2044-2050.
50. Yu, H., E.P. Diamandis, M. Levesque, S.L. Asa, M. Monne, and C.M. Croce 1995 Expression of the prostatic specific antigen gene by a primary ovarian carcinoma. Cancer Res., 55:1603-1606.